| Literature DB >> 35566771 |
Lorenzo Spirito1, Michele Morelli2,3,4, Roberto La Rocca1, Luigi Napolitano1, Claudia Collà Ruvolo1, Lorenzo Romano4, Angelo di Giovanni1, Carmine Sciorio4, Sergio Concetti5, Emanuele Montanari2,3, Francesca Tripodi6, Ferdinando Fusco1, Marco Capece1.
Abstract
We performed a monocentric longitudinal study on sexually active male patients, from May 2021 to October 2021, with SARS-CoV-2 infection confirmed with a nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR). The questionnaires were delivered by email. The study period was divided into the periods before getting tested (T1), during quarantine (T2), 1 month after a negative test (T3), and 3 months after a negative test (T4). All participants were invited to complete these questionnaires: 10- and 6-item questionnaires, a sexual distress schedule (SDS), and the international index of erectile function questionnaire of 15 items (IIEF-15). The primary endpoint was to evaluate the impact of quarantine on male sexual function (SF) during and after the SARS-CoV-2 infection. A total of 22 male patients met the inclusion criteria. The differences for both SDS and IIEF-15 scores, between T1-T2 (27 (IQR 24.0-32.2) vs. 37.5 (IQR 34.2-45.5), 45 (IQR 38.0-50.2) vs. 28.5 (IQR 19.5-38.0)), T2-T3 (37.5 (IQR 34.2-45.5) vs. 28 (IQR 24.0-31.0), and 28.5 (IQR 19.5-38.0) vs. 39.5 (IQR 35.5-44.2)) were statistically significant (p < 0.001), respectively. Moreover, between T1-T4, no statistically significant difference (p > 0.05) was recorded in both SDS (27 (IQR 24.0-32.2) vs. 26.5 (IQR 24-30.2)) and IIEF-15 (45 (IQR 38.0-50.2) vs. 28.5 (IQR 19.5-38.0)). In 20 patients (90.9%), SARS-CoV-2 had a huge impact on relationship and sexual life, but no patient attended a clinic for sexual difficulties. In conclusion quarantine has negatively influenced SF in infected patients; however, 3 months after the rRT-PCR negative test, a promising return to the preinfection SF values is observed.Entities:
Keywords: COVID-19; erectile function; sexual satisfaction; sexual well-being
Year: 2022 PMID: 35566771 PMCID: PMC9100217 DOI: 10.3390/jcm11092645
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Descriptive characteristics of 22 COVID-19 patients.
| Overall Population | 22 (100) | |
|---|---|---|
|
| Median (IQR) | 63 (58.2–67) |
|
| Male | 22 (100) |
| Female | 0 (0) | |
|
| <25 | 9 (40.9) |
| 25–30 | 11 (50.0) | |
| ≥30 | 2 (9.1) | |
|
| 0 | 10 (45.5) |
| 5 | 1 (4.5) | |
| 10 | 6 (27.3) | |
| 20 | 5 (22.7) | |
|
| Median (IQR) | 3 (1–4) |
|
| 0 | 2 (9.1) |
| 1 | 17 (77.3) | |
| 2 | 3 (13.6) | |
|
| Degree | 8 (36.4) |
| Primary school | 4 (18.2) | |
| Secondary school | 10 (45.5) | |
|
| Employed | 10 (45.5) |
| Retired | 4 (18.2) | |
| Self-employment | 6 (27.3) | |
| Unemployed | 2 (9.1) | |
|
| No | 21 (95.5) |
| Yes | 1 (4.5) | |
|
| No | 13 (59.1) |
| Yes | 9 (40.9) | |
|
| Mean | 11.22 (4.15) |
| Median (IQR) | 10 (8–13) | |
|
| No | 17 (77.3) |
| Yes | 5 (22.7) |
Questionnaire administrated to 22 COVID-19 patients before COVID-19 testing (Time 1), during quarantine (Time 2), and 1 month after a negative test (Time 3).
| Questions | Answers | Time 1 | Time 2 | Time 3 |
|---|---|---|---|---|
| (1) Did you have complete sexual intercourse (vaginal) during this time? | No | 1 (4.5) | 17 (77.3) | 6 (27.3) |
| Yes | 21 (95.5) | 5 (22.7) | 16 (72.7) | |
| (2) How often did you have sexual intercourse? | Never | 1 (4.5) | 16 (72.7) | 6 (27.3) |
| Less than once per month | 2 (9.1) | 1 (4.5) | 5 (22.7) | |
| Once a month | 6 (27.3) | 2 (9.1) | 6 (27.3) | |
| More than once a month | 8 (36.4) | 3 (13.6) | 4 (18.2) | |
| More than once a week | 5 (22.7) | 0 (0) | 1 (4.5) | |
| Once a day | 0 (0) | 0 (0) | 0 (0) | |
| More than one a day | 0 (0) | 0 (0) | 0 (0) | |
| (3) How often did you masturbate? | Never | 11 (50.0) | 14 (63.6) | 9 (40.9) |
| Less than once per month | 7 (31.8) | 2 (9.1) | 10 (45.5) | |
| Once a month | 4 (18.2) | 0 (0) | 3 (13.6) | |
| More than once a month | 0 (0) | 6 (27.3) | 0 (0) | |
| More than once a week | 0 (0) | 0 (0) | 0 (0) | |
| Once a day | 0 (0) | 0 (0) | 0 (0) | |
| More than one a day | 0 (0) | 0 (0) | 0 (0) | |
| (4) How often did you watch porn? | Never | 14 (63.6) | 18 (81.8) | 14 (63.6) |
| Less than once per month | 6 (27.3) | 1 (4.5) | 8 (36.4) | |
| Once a month | 2 (9.1) | 0 (0) | 0 (0) | |
| More than once a month | 0 (0) | 3 (13.6) | 0 (0) | |
| More than once a week | 0 (0) | 0 (0) | 0 (0) | |
| Once a day | 0 (0) | 0 (0) | 0 (0) | |
| More than one a day | 0 (0) | 0 (0) | 0 (0) | |
| (5) Were you having sexual difficulties? | No | 0 (0) | 0 (0) | 0 (0) |
| Yes | 22 (100) | 22 (100) | 22 (100) | |
| (6) If Yes, have you ever had such difficulties? | No | 0 (0) | 0 (0) | 0 (0) |
| Yes | 22 (100) | 22 (100) | 22 (100) | |
| (7) Did you attend a clinic for your difficulties? | No | 20 (90.9) | 22 (100) | 22 (100) |
| Yes | 2 (9.1) | 0 (0) | 0 (0) |
COVID-19 positivity period.
| Questions | 22 (100%) | |
|---|---|---|
| 1. Could you easily self-isolate? | No | 14 (63.6) |
| Yes | 8 (36.4) | |
| 2. Are you worried at the moment for yourself? | No | 13 (59.1) |
| Slightly worried | 6 (27.3) | |
| Moderately worried | 3 (13.6) | |
| Very worried | 0 (0) | |
| 3. Are you worried at the moment for your relatives? | No | 5(22.7) |
| Slightly worried | 4 (18.2) | |
| Moderately worried | 12 (54.5) | |
| Very worried | 1 (4.5) | |
| 4. Have you followed the quarantine protocols? | Completely | 22 (100) |
| 5. Did it impact on your physical health? | Not at all | 1 (4.5) |
| Not very much | 6 (27.3) | |
| Very much | 7 (31.8) | |
| Completely | 8 (36.4) | |
| 6. Did it impact on your mental health? | Not at all | 1 (4.5) |
| Not very much | 7 (31.8) | |
| Very much | 10 (45.5) | |
| Completely | 4 (18.2) | |
| 7. Did the COVID-19 emergency impact on your relationship? | Not at all | 1 (4.5) |
| Not very much | 6 (27.3) | |
| Very much | 9 (40.9) | |
| Completely | 6 (27.3) | |
| 8. How did the COVID-19 emergency impact on all aspects of your relationship? | Made them much worse | 8 (36.4) |
| Made them worse | 12 (54.5) | |
| Stayed the same | 2 (9.1) | |
| Made them better | 0 (0) | |
| Made them much better | 0 (0) | |
| 9. How did the COVID-19 emergency impact on your sexuality? | Very badly | 13 (59.1) |
| Badly | 7 (31.8) | |
| No difference | 2 (9.1) | |
| Improved | 0 (0) | |
| Much improved | 0 (0) | |
| 10. Did you receive any information or advice regarding the sexual intercourse during COVID-19 emergency? | No | 22 (100) |
| 11. Did you receive any information or advice regarding having pregnancy during COVID-19 emergency? | No | 22 (100) |
Figure 1Box and whisker plots depicting sexual dysfunction (A) and erectile function (B) from the total points of the questionnaire administrated to 22 COVID-19 patients in the periods before being tested (Time 1), during quarantine (Time 2), 1 month after a negative test (Time 3), and 3 months after a negative test (Time 4). Boxes denote the interquartile range. The solid black horizontal bar denotes the median within each time period. Whiskers denote the 95% range of the distribution of tumor size. The open circles denote outlier values.
Sexual distress schedule administrated to 22 COVID-19 patients in the periods before being tested (Time 1), during quarantine (Time 2), 1 month after a negative test (Time 3), and 3 months after a negative test (Time 4).
| Wilcoxon Sign Rank Test | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time 1 | Time 2 | Time 3 | Time 4 | Time 1 vs. Time 2 | Time 2 vs. Time 3 | Time 3 vs. Time 4 | Time 1 vs. Time 3 | Time 1 vs. Time 4 | Time 2 vs. Time 4 | ||
|
| Median | 2 | 3 | 2 | 2 | 0.001 | 0.001 | 0.3 | 0.3 | 1.0 | 0.001 |
| IQR | 2–2.8 | 2.2–4.0 | 2.0–2.0 | 2.0–2.8 | |||||||
|
| Median | 2 | 3 | 2 | 2 | <0.001 | 0.001 | 0.2 | 0.2 | 1.0 | <0.001 |
| IQR | 2.0–2.8 | 3.0–4.0 | 2.0–3.0 | 2.0–2.8 | |||||||
|
| Median | 2 | 3 | 2 | 2 | 0.002 | <0.001 | 1.0 | 0.3 | 0.3 | 0.001 |
| IQR | 2.0–3.0 | 3.0–4.0 | 2.0–3.0 | 2.0–3.0 | |||||||
|
| Median | 2 | 3 | 2 | 2 | 0.001 | 0.001 | 0.2 | 0.5 | 0.3 | <0.001 |
| IQR | 2.0–3.0 | 3.0–4.0 | 2.0–3.0 | 2.0–2.8 | |||||||
|
| Median | 2 | 3.5 | 2 | 2 | 0.004 | 0.01 | 0.2 | 0.2 | 1.0 | <0.01 |
| IQR | 2.0–3.0 | 3.0–4.0 | 2.0–3.8 | 2.0–3.0 | |||||||
|
| Median | 2 | 3 | 2 | 2 | 0.005 | <0.001 | 0.8 | 0.3 | 1.0 | <0.01 |
| IQR | 2.0–3.0 | 3.0–4.0 | 2.0–3.0 | 2.0–3.0 | |||||||
|
| Median | 2 | 3 | 2 | 2 | 0.03 | 0.09 | 0.2 | 0.2 | 1.0 | 0.03 |
| IQR | 2.0–3.0 | 2.0–4.0 | 2.0–3.0 | 2.0–2.8 | |||||||
|
| Median | 2 | 3 | 2 | 2 | <0.001 | <0.001 | 0.2 | 1.0 | 0.1 | <0.001 |
| IQR | 2.0–2.0 | 3.0–4.0 | 2.0–2.0 | 2.0–2.0 | |||||||
|
| Median | 2.5 | 3 | 2 | 2.5 | 0.04 | 0.01 | 0.4 | 0.1 | 1.0 | 0.03 |
| IQR | 2.0–3.0 | 3.0–4.0 | 2.0–3.0 | 2.0–3.0 | |||||||
|
| Median | 2 | 3 | 2 | 2 | <0.01 | 0.01 | 0.07 | 0.1 | 1.0 | <0.01 |
| IQR | 2.0–3.0 | 2.2–4.0 | 2.0–3.0 | 2.0–3.0 | |||||||
|
| Median | 2 | 3 | 2 | 2 | <0.001 | 0.01 | 0.01 | 0.03 | 1.0 | <0.001 |
| IQR | 2.0–2.0 | 3.0–4.0 | 2.0–3.0 | 2.0–2.0 | |||||||
|
| Median | 2 | 3 | 2 | 2 | <0.01 | <0.01 | 0.1 | 1.0 | 0.1 | <0.001 |
| IQR | 2.0–3.0 | 3.0–4.0 | 2.0–3.0 | 2.0–3.0 | |||||||
|
| Median | 27 | 37.5 | 28 | 26.5 | <0.001 | <0.001 | 0.06 | 0.8 | 0.1 | <0.001 |
| IQR | 24–30.2 | 34.2–45.5 | 24.0–31.0 | 24.0–30.2 | |||||||
International index of erectile function (IIEF) questionnaire administrated to 22 COVID-19 patients in the periods before COVID 19 testing (Time 1), during quarantine (Time 2), 1 month after a negative test (Time 3), and 3 months after a negative test (Time 4).
| Wilcoxon Sign Rank Test | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time 1 | Time 2 | Time 3 | Time 4 | Time 1 vs. Time 2 | Time 2 vs. Time 3 | Time 3 vs. Time 4 | Time 1 vs. Time 3 | Time 1 vs. Time 4 | Time 2 vs. Time 4 | ||
|
| Median | 15 | 10 | 13 | 14 | <0.001 | <0.001 | 0.07 | <0.001 | 0.07 | <0.001 |
| IQR | 12.2–18.5 | 5.0–12.0 | 10.2–15.8 | 10.0–18.5 | |||||||
|
| Median | 5 | 4.5 | 5 | 5 | <0.001 | <0.001 | 0.5 | 0.01 | 0.3 | <0.001 |
| IQR | 5.0–6.8 | 2.0.2–5 | 5.0–5.8 | 5.0–6.0 | |||||||
|
| Median | 7 | 5 | 5 | 5.5 | <0.001 | 0.3 | 0.01 | <0.001 | 0.1 | <0.01 |
| IQR | 5.0–8.0 | 2.2–6.8 | 3.2–7.0 | 5.0–8.0 | |||||||
|
| Median | 10 | 5 | 9 | 10 | <0.001 | 0.001 | 0.06 | 0.01 | 1.0 | <0.001 |
| IQR | 8.0–10.8 | 5.0–7.8 | 7.2–10.0 | 8.0–10.0 | |||||||
|
| Median | 7 | 5 | 7 | 7 | <0.001 | 0.004 | 0.5 | 0.053 | 0.2 | 0.001 |
| IQR | 6.0–8.0 | 3.0–6.8 | 6.0–8.0 | 6.0–8.0 | |||||||
|
| Median | 45 | 28.5 | 39.5 | 42 | <0.001 | <0.001 | <0.01 | <0.001 | 0.09 | <0.001 |
| IQR | 38.0–50.2 | 19.5–38.0 | 35.5–44.2 | 36.0–48.0 | |||||||